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Colorectal cancer continues to increase in incidence and the
disease remains the second most common cause of cancer-related
deaths (Steele, 1994). The prognosis of patients with colorectal
cancer depends on the TNM stage of the tumour, in particular
lymph-node involvement, and whether or not the tumour is
completely resected (R0) (Ratto et al, 1998). Despite careful
histopathological assessment of resected lymph nodes, up to 20%
of all node-negative patients with a curative resection develop
tumour recurrence (Hermanek, 1995). The best explanation for
this is that tumour cells have already spread beyond the area of
resection before removal of the tumour, but are undetectable by
routine staging methods. Efforts to detect such minimal residual
disease have centered on the use of highly sensitive techniques for
tumour cell detection in lymph nodes, bone marrow and peripheral
blood.
Various methods including fat clearance (Cawthorn et al, 1986),
multiple serial sections (Zhang et al, 1998) and immunohisto-
chemistry (Davidson et al, 1990; Cutait et al, 1991; Calaluce et al,
1998; Natsugoe et al, 1998; Oeberg et al, 1998), have been devel-
oped, but none of these have become useful in a daily routine
examination of lymph nodes.
RT-PCR (reverse transcriptase polymerase chain reaction) for
the detection of mRNA has been proven to be an effective and
highly sensitive method for detecting tumour-associated mRNA
transcription (Raj et al, 1998). Despite various clinical studies
using RT-PCR to detect ‘micrometastatic tumour cells’ in lymph
nodes, the clinical significance of these results is still unclear
(Mori et al, 1995; 1998; Demeure et al, 1998; Futamura et al,
1998; Liefers et al, 1998). One reason for this may be that the high
sensitivity of the method allows the detection of mRNA, but the
tumour cells which express this mRNA may not be responsible for
the development of recurrent disease. It is possible that some
detected tumour cells are biologically inactive, due to an intrinsic
dormancy or an immunological filter function of lymph nodes. In
addition, false-positive detection may result from amplification of
non-cancer-specific tissue (illegitimate transcription) (Henke and
Loening, 1998). Therefore further evaluation of the clinical and
prognostic value of mRNA detection by RT-PCR is needed.
One of the most commonly used targets of RT-PCR for tumour
cell detection is the carcinoembryonic antigen (CEA) (Raj et al,
1998). But few studies using CEA RT-PCR for detection of
tumour cell mRNA in lymph nodes have been performed in
colorectal carcinoma (Mori et al, 1995; 1998; Futamura et al,
1998; Liefers et al, 1998). A valuable clinical correlation between
CEA mRNA detection and prognosis has only been described in
one study with a small cohort of patients (Liefers et al, 1998).
Cytokeratins (CK) are also a frequent target for RT-PCR tumour
cell detection, but detection of CK is complicated by the existence of
CK-18 and 19 pseudogenes (Neumaier et al, 1995; Ruud et al, 1999).
CK-20 has been shown to be a specific marker of gastrointestinal
epithelial cells (Moll et al, 1992), has been used for the detection of
tumour cell involvement (Futamura et al, 1998; Funaki et al, 1998)
and has the advantage that no CK-20 pseudogenes have been identi-
fied. Recently, Jung et al (1999) described a background mRNA
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doi: 10.1054/ bjoc.2000.1442, available online at http://www.idealibrary.com on expression of CK-20 in granulocytes of non-cancer patients, which
has to be further evaluated. Combination of various mRNA targets
may also help to improve the clinical usefulness of the analysis.
We carried out the present study in order to further investigate
the clinical value of CEA and CK-20 mRNA detection by RT-PCR
in regional lymph nodes of patients who had undergone a complete
resection of their colorectal tumour and had no detectable lymph-
node metastasis by routine methods. We limited our analysis to
two peritumoural lymph nodes per case to simulate a technique
which might be applicable to a routine clinical setting in the future.
The results of mRNA detection were compared with tumour recur-
rence and patient survival data.
MATERIAL AND METHODS
Patient group
The patient study group consisted of 51 consecutive patients with
colorectal cancer who underwent resection in our department
between 1990–1992 (Table 1). The mean of patient age was 60.4
years and there were 25 males and 26 females. Tumour recurrence
and survival data were available from all 51 patients with a median
follow-up time of 94 months (range 10–102 months). The overall
5-year survival rate for the 51 patients was 87.5%. Twelve patients
had developed recurrent disease during the follow-up period.
Distant metastases were confirmed in nine patients (liver metas-
tases in eight cases and lung metastasis in one case), local recur-
rence with or without lymph-node metastasis, was detected in
three patients (Table 1). Of these 12 patients none were alive at the
end of follow-up, 11 patients (91.7%) had died of recurrent disease
and one patient died of a cause unrelated to his cancer. The control
group consisted of 10 patients with chronic inflammatory bowel
disease who were operated upon in our department.
Tumours
In order to be included in the study, the tumours needed to be
entirely resected (UICC R0) and the lymph nodes found to be free
of tumour cells (pN0) by histopathological examination. Thirty-
eight of the 51 tumours were located in the colon and 13 were from
the rectum. The resection procedure performed consisted of one
abdominoperineal resection, 12 (low) anterior resections, seven
sigmoid resections, 11 left hemicolectomies and 20 right (radical)
hemicolectomies. The extent of the lymph-node dissection was
performed according to oncological recommendations (Ruo et al,
1998). According to staging based on the TNM classification, 15
tumours (29.4%) were stage I (pT1 = 5, pT2 = 10) and 36 (70.6%)
were stage II (pT3 = 32, pT4 = 4). Histologically, 43 (84.3%)
tumours were tubulopapillary adenocarcinomas, the other eight
(15.7%) were mucinous adenocarcinomas. Between six and 72
lymph nodes were resected along with the tumours (median of 29),
seven of the specimens (13.7%), had less than 12 removed nodes.
Immunohistochemical CEA and CK-20 staining was performed on
all 51 primary tumours, which confirmed that all of the primary
colorectal carcinomas expressed both CEA and CK 20.
Lymph-node sampling
To simulate a technique that might be clinically feasible two
lymph nodes from each resection specimen (a total of 102 lymph
nodes) were taken, that were located nearest to the primary tumour
(peritumoural lymph nodes). After division into two halves, one
half was used for routine pathological examination and the other
was immediately frozen and stored in liquid nitrogen until use.
Thirty cryostat sections of 15 mm thickness were prepared for
RNA extraction from each frozen tissue sample. One 6 mm frozen
section was prepared before and one after the 30 serial sections
and examined with a haematoxylin and eosin (HE) staining to
confirm that no tumour cells were present histologically.
RNA extraction
The silica gel-based membrane system RNeasy (Quiagen) was
used for extraction of total RNA from the lymph-node samples
and the tumour cell lines. The amount of total RNA was measured
with a spectrophotometer at 260 nm and 280 nm wavelengths.
Approximately 40–60 mg of total RNA from each lymph-node
sample was extracted.
Controls
Tumour cell lines were used as positive controls. The CEA- and
CK-20-positive tumour cell lines CaCo-2 (colorectal cancer) and
MCF-7 (breast cancer) were grown in cell culture in RPMI or
DMEM medium, and were counted in a haematocytometer
(Neubauer chamber) prior to RNA extraction. The expression
level of CEA in the supernatant of the MCF-7 cells was approxi-
mately double of that of the CaCo-2 cells. The pooled RNA of 14
primary colorectal carcinomas displaying high levels of CEA and
CK-20 was used as an additional positive control. As negative
controls, mRNA from lymph nodes obtained from patients with
chronic inflammatory bowel disease were examined to evaluate
the level of CEA expression in normal lymph nodes of non-cancer
patients. These lymph nodes remained negative for both markers
throughout the experiments. Efficient amplification of the RNA
was monitored by a control PCR for b2-microglobulin using the
primers M1: 5¢-CCT GAA TTG CTA TGT GTC TGG GTT 
TCA-3¢ and M2: 5¢-GGA GCA ACC TGC TCA GAT ACA TCA
AAC-3¢. Efficient RNA amplification was consistently obtained
from all samples.
Primers
CEA oligonucleotide primers for RT-PCR based on the published
sequence of the CEA gene (Schrewe et al, 1990) were used for
CEA mRNA detection as published by Gerhard et al (1994).
For detection of CK-20 mRNA, a set of published CK-20 specific
primers was used (Funaki et al, 1998).
RT-PCR reactions
The RT-PCR reactions were performed in a Landgraf Varius-V
thermocycler with the TitanTM One Tube RT-PCR and PCR 
Master kits (Boehringer Mannheim, Germany). The reactions
were carried out in a reaction volume of 50 ml with 2 mg of total
RNA per sample. For CEA amplification the following conditions
were used: reverse transcription at 50°C for 30 min, template
denaturation at 94°C for 2 min, 10 cycles including denaturation at
94°C for 30 s, annealing at 69°C for 30 s and elongation at 68°C
for 45 s, another 20 cycles under the same conditions followed by
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the CK-20 RT-PCR were as follows: reverse transcription at 50°C
for 30 min, template denaturation for 5 min at 93°C, 10 cycles of
denaturation (1 s at 94°C), annealing (20 s at 63°C), elongation
(10 s at 72°C), 35 more cycles under the same conditions and a
final step for 5 min at 72°C.
Gel electrophoresis was performed on 2% agarose gels. As
length standards HPA II, Dra I and Hind III digested DNA of
pUCBM21 (DNA-length standard VIII, Boehringer Mannheim)
were used. The amplified DNA fragments were 160 bp for the CEA
primer pairs and 370 bp for the CK-20 primer pairs. Sequencing of
these PCR products confirmed that the selected portion of the target
mRNA had been amplified (data not shown). During initial testing
of the method, nested PCR with additional primers (not shown) was
performed, but did not improve the results, so the analysis of the
lymph nodes was performed with RT-PCR alone.
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Table 1 Patient characteristics in comparison to tumour mRNA detected by RT-PCR
Patients UICC Histology Resected pT Operation RT-PCR detection Outcome Disease-free
stage nodes CEA CK-20 Vital Disease status survival 
(months)
01 II T 31 4 1 + + DOD recurrencea 39
02 II T 57 3 4 + + alive NED 101
03 II M 52 3 5 – + alive NED 128
04 I T 32 2 3 + + DOD recurrenceb 24
05a I T II 1 2 + – DOD recurrenceb 71
06 II M 40 3 5 + + DOD recurrenceb 56
07 II M 52 3 4 – – alive NED 122
08 II T 12 4 2 + + alive NED 122
09 II T 32 3 2 – – alive NED 121
10 II T 44 3 5 – – alive NED 60
11 II T 17 3 2 + + alive NED 119
12 II T 72 4 4 + – alive NED 119
13 II T 22 3 3 + + alive NED 119
14 II T 32 3 3 – – DUC NED 22
15 II T 61 3 5 – + alive NED 116
16 I T 43 2 5 + + DUC recurrenceb 29
17 II T 14 3 4 – – alive NED 115
18 II T 21 3 5 + + DUC NED 44
19 I T 19 1 5 – + alive NED 42
20a II T 7 3 4 + + alive NED 103
21 II T 33 3 4 – – DUC NED 10
22 II T 24 3 2 + + DOD recurrencec 16
23 II T 44 3 4 + – alive NED 102
24 II T 29 3 5 – – alive NED 102
25 II T 35 3 2 + + DOD recurrenceb 61
26 I T 31 2 4 + + alive NED 100
27 II M 22 3 4 – – DOD recurrencec 16
28 I M 39 2 2 – + DOD recurrenceb 66
29 II T 25 3 5 + + alive NED 96
30 II T 34 3 5 + + alive NED 96
31 I T 49 1 4 + – alive NED 95
32 II M 30 3 5 – + alive NED 95
33 II T 23 3 5 – – alive NED 94
34 II T 28 3 5 – – DUC NED 54
35 I T 33 2 2 + + DUC NED 75
36 II T 26 4 3 + – alive NED 94
37a II T 8 3 3 + + DOD recurrenceb 40
38 II M 38 3 5 + + alive NED 92
39 I T 14 2 2 + + alive NED 91
40 II T 25 3 5 – – alive NED 91
41 II T 38 3 3 + – alive NED 89
42a I T 7 2 2 – – alive NED 88
43 I T 18 2 5 – + alive NED 88
44 II T 51 3 5 + + alive NED 87
45a I T 11 1 2 + + DOD recurrencec 18
46 I T 20 2 3 + + alive NED 86
47a II M 10 3 5 – + alive NED 86
48 II T 29 3 4 + + alive NED 85
49 II T 20 3 2 + + alive NED 84
50 I T 50 1 5 – – alive NED 85
51a I T 6 2 5 – – DOD recurrenceb 2
a = less than 12 resected lymph nodes; T = tubulo-papillary; M = mucinous adenocarcinoma; Operation: 1 = abdominoperineal resection; 2 = (low) anterior
resection; 3 = sigmoid resection; 4 = left (radical) hemicolectomy; 5 = right (radical) hemicolectomy. Recurrent site: bdistant metastasis (liver n = 8, lung n = 1),
clocal recurrence; DOD = died of disease; DUC = died of cancer-unrelated cause; NED = no evidence of diseaseSensitivity testing
Using the colon and breast cancer cell lines CaCo-2 and MCF-7,
dilution series of RNA equivalent to 106, 105, 104, 103, 102, 10 and
one tumour cells in 106 mononuclear cells were performed.
Statistical analysis
For group comparisons the c2-test was used. A difference of 
P < 0.05 was considered to be significant. Group oriented curves
for recurrence-free survival were calculated according to the
method of Kaplan and Meier. The significance of differences
between groups was examined using the log-rank test. Survival
analysis was performed for the total patient group (n = 51) and, in
addition, for the subgroup of 44 patients, who had at least 12 resected
lymph nodes, according to the recommendations of the UICC.
RESULTS
Sensitivity testing
Using the cell lines CaCo-2 and MCF-7, the dilution series of
RNA indicated that both primer pairs were able to detect an
amount of mRNA equivalent to one tumour cell in 106 mono-
nuclear cells (Figure 1).
Detection
One hundred and two lymph nodes of 51 patients with colorectal
cancer and 20 lymph nodes of 10 patients with chronic inflamma-
tory bowel disease were analysed. All lymph nodes from the cases
with inflammatory, non-neoplastic disease were negative for both
CEA- and CK-20 mRNA.
The examination of the lymph nodes of 51 patients with
colorectal disease detected CK-20 mRNA in 31 patients (60.8%)
(Table 2, Figure 2). CEA mRNA was positive in 30 cases by RT-
PCR analysis (58.8%). A total of 37 patients (72.5%) expressed
either CEA or CK-20, or both. Identical expression patterns for
CK-20 and CEA (both negative or both positive) were found in 38
of 51 patients (74.5%), with the remaining 13 cases (25.5%)
showing discrepant results between the two sets of primers.
Correlation with histopathologic findings
A comparison of CEA RT-PCR positivity in lymph nodes and the
histologic type of the tumour showed that a significantly higher
percentage of regional lymph nodes of tubulopapillary adenocarci-
noma (28 of 43 = 65.1%) vs mucinous adenocarcinomas (2 of 8 =
25%) expressed CEA (P ≤ 0.03). No such significant difference
according to histologic type was seen for CK-20. Also, no correla-
tion was found between positive RT-PCR reactions and tumour
site, depth of invasion (pT category), CEA serum level, presence
of lymphatic vessel invasion or the histologic grade of the tumour.
Correlation with recurrence and prognosis
Twelve of 51 patients (23.5%) developed recurrent disease (Table 1)
and died during the follow-up period (median follow-up time 94
months). Of these 12 patients with recurrent disease, nine had
positive lymph nodes for CK-20 mRNA and CEA mRNA
(75.0%). Three cases were not detected by the CK-20 and CEA
primers (25.0%), a difference which was statistically not signifi-
cant. The site of recurrence (nine cases with distant metastases and
three with local recurrent disease) had no impact on the detection
rates (Table 1). Eight of the nine patients (89%), who developed
distant metastasis were detected either by CK-20 PCR or by CEA
PCR. Of the three patients who developed local recurrent disease,
two patients (67%) were detected by RT-PCR analysis. Positive
mRNA detection in cases without tumour recurrence during the
follow-up period (n = 39) was found in 22 cases (56.4%) for CK-
20 and in 21 cases (53.8%) for CEA.
In order to avoid the problem of stage migration (Will Rodgers
phenomenon, Schlag, 1998), the results of the RT-PCR reactions
of seven patients (13.7%) with fewer than 12 resected lymph
nodes (pNx) were excluded and also analysed for clinical
outcome. Eight of 44 remaining patients (18.2%) had developed
recurrent disease. Of these eight patients, seven patients were
identified to have positive lymph nodes for CK-20 mRNA
(87.5%). Only one case (12.5%) was not detected by the CK-20
primer (P = 0.09). For CEA, six of the eight patients with recurrent
disease had positive lymph nodes by RT-PCR (75.0%) and two
cases were not detected by CEA RT-PCR (25.0%).
No statistical difference concerning the rate of positivity
between patients with and without recurrence was seen for CEA
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Figure 1 10-fold serial dilutions of RNA equivalent to 105–0 tumour cells
(cell line MCF-7) in 10 6 mononuclear cells which demonstrates the sensitivity
of the RT-PCR assays for CEA (A) and CK-20 (B). Both methods were able
to detect one tumour cell in 106 normal cells. DNA fragments were run in a
2% agarose gel. Negative controls obtained from lymph nodes with chronic
inflammatory bowel disease were shown (marked as neg.). The DNA length
standard VIII (Boehringer Mannheim) is shown in lane Sand CK-20. The combination of the results for CK-20 and CEA
resulted in no advantage as well. A longer disease-free survival
was seen for patients with lymph nodes negative for CK-20 RT-
PCR vs patients with lymph nodes positive by CK-20 RT-PCR
reaction (n.s.). CEA RT-PCR showed also a tendency to identify
patients with longer disease-free survival (Figure 3).
DISCUSSION
Based on our results and data from the literature, RT-PCR for the
detection of CK-20 mRNA and CEA mRNA in clinically sampled
regional lymph nodes of pN0 colorectal cancer appears to be a
promising tool for the identification of patients at high risk of
tumour recurrence. Our study included 51 cases of colorectal
cancer with a long follow-up period of 94 months, in which the
lymph nodes were found to be negative for tumour by routine
histopathologic methods. We limited our analysis to two lymph
nodes per case, which were selected as the nearest detectable
nodes to the primary tumour. We suggest that such a strategy might
be applicable to a routine clinical setting. Our results support the
clinical usefulness of such a strategy, because the RT-PCR exami-
nation of only two resected peritumoural lymph nodes predicts the
risk of tumour recurrence in 75% of cases.
The significance of ‘micrometastatic’ detection by RT-PCR as a
marker for prediction of distant metastasis or local recurrence is
still unclear. Our results show a tendency regarding distant metas-
tasis. CEA was used as a target for detection of tumour mRNA
because of existing clinical data. CK-20 was chosen as an addi-
tional target since, unlike CK-18 and CK-19, there are no pseudo-
genes and it is almost always expressed by colorectal carcinomas
(Moll et al, 1992). The potential role of CK-20-specific RT-PCR to
evaluate ‘micrometastasis’ was demonstrated by Yun et al (2000),
who validated CK-20 as a specific marker of submicroscopic
lymph-node metastases in colorectal cancer by its correlation to K-
RAS mutations. This underlined the concept that what is detected
by RT-PCR represents occult metastatic disease.
Previous studies have described the use of RT-PCR targeting
cytokeratins or CEA for the detection of occult tumour cells, but a
lack of clinical data or the various methods which have been used
have complicated the assessment of the clinical significance of
these findings (Table 3). Mori et al (1995; 1998) reported the
detection of tumour cells in the regional lymph nodes of gastro-
intestinal and breast carcinomas using the same primers for CEA
RT-PCR which we used in our study (Gerhard et al 1994). The
authors concluded that RT-PCR was a powerful tool for the detec-
tion of tumour cell deposits in lymph nodes, but only a few of the
tumours examined were colorectal carcinomas and, additionally, no
reliable statement about the clinical impact of tumour cell detection
by this method could be made (Mori et al, 1995; 1998). A combined
RT-PCR analysis for CEA and CK-20 mRNA in lymph nodes from
13 patients with colorectal cancer in another study revealed that
100% of these had positive lymph nodes by one or both primers
(Table 3), but no survival analysis was performed (Futamura et al,
1998). The only study which demonstrated a significant correlation
between the presence of CEA mRNA in regional lymph nodes and
survival was performed by Liefers et al (1998). This study included
only 26 patients with stage II colorectal cancer and did not provide a
practical approach for routine clinical use.
Our RT-PCR results for CEA, utilizing primers which have been
used in above-mentioned previous studies (Gerhard et al, 1994),
showed different expression patterns in 25% of our samples in
comparison to that detected with CK-20 RT-PCR. We detected
CK-20 and/or CEA mRNA in the lymph nodes of 37 of 51 patients
(72.5%), while 31 and 30 cases, respectively, were positive for
either one of the markers. Expression patterns between CEA and
CK-20 (both negative or both positive) were identical in 38 of 51
cases (74.5%). The high RT-PCR detection of CK-20 and/or CEA
mRNA of 75% in lymph nodes of patients who developed recur-
rent disease or distant metastasis during the long follow-up time,
indicate a potential role for CK-20 and CEA as markers for detec-
tion of prognostically relevant tumour cell deposits in regional
lymph nodes of colorectal cancer patients. In addition, our CEA
data reflect the complexity of CEA expression and its potential
heterogeneity in tumour-associated lymph nodes. They also show
differences in expression between histological subtypes of
tumours (tubulopapillary and mucinous adenocarcinomas).
Although studies which have shown a significant correlation of
RT-PCR tumour mRNA detection and prognosis are reported in
the literature, the RT-PCR method still confronts us with problems
that need to be solved. One is that detection of tumour mRNA may
not always show a correlation with patient survival or the proba-
bility of tumour recurrence. In our series the high rate of detection
of CEA or CK-20 mRNA in 53% or 56% of patients who devel-
oped no recurrent disease suggests either that the detected tumour
cells were not of clinical significance because of their biological
characteristics or there was contamination of the specimen during
the processing of the lymph nodes (‘false-positive’ results). Thus,
mRNA detection did not reach statistical significance for either the
prediction of tumour recurrence or disease-free survival.
CEA and CK-20 mRNA in lymph nodes of colorectal carcinoma 1327
British Journal of Cancer (2000) 83(10), 1323–1329 © 2000 Cancer Research Campaign
370 bp
160 bp
441 bp
123
Neg. control
456
Pos. control
789
Patient no. 1
10 11 12 13
Patient no. 16
Figure 2 Amplified DNA fragments from the lymph-node samples of two
patient (patient 1 and 16, Table 1) obtained by the two RT-PCR methods
(lanes 7–12). Negative control of patients with inflammatory bowel disease is
demonstrated on lanes 1–3. As positive control pooled RNA of colorectal
carcinoma was used, shown on lanes 4–6. The CEA-specific cDNA
fragments amplified by RT-PCR had a length of 160 bp (lanes 6, 9, 12), the
CK-20 specific fragment was 370 bp long (lanes 5, 8, 11). In lanes 1, 4, 7 and
10 the b2-microglobulin-specific fragment is seen, indicating efficient RNA
amplification. The DNA length standard VIII is shown in lane 13
Table 2 Detection of CK-20 mRNA and CEA mRNA in lymph nodes of
patients with and without recurrent disease during follow-up (not significant)
RT-PCR No recurrence Recurrence
n = 39 (76.5%) n = 12 (23.5%)
CK-20 CEA CK-20 CEA CK-20 CEA
Neg. 20/51 21/51 17/39 18/39 3/12 3/12
(39.2%) (41.2%) (43.6%) (46.2%) (25.0%) (25.0%)
Pos. 31/51 30/51 22/39 21/39 9/12 9/12
(60.8%) (58.8%) (56.4%) (53.8%) (75.0%) (75.0%)These results fit with the concept that detected tumour cells in
the lymph nodes are not biologically active metastases, but are
‘epiphenomena’, with very little impact on patient prognosis.
Based on the morphology of immunohistochemically detected
tumour cell deposits, these can be classified as either micrometas-
tases, when they display a surrounding reaction and are presumably
biologically active, or as tumour cell microinvolvement, when such
a reaction is not present and the cells may be in a biologically
inactive state (Natsugoe et al, 1998). This morphologic distinction
between types of involvement is not possible with RT-PCR based
methods.
A further problem for sensitive molecular techniques may be
the possibility that some normal cells express very small amounts
of target mRNA which may interfere with specific expression by
epithelial or tumour cells (illegitimate transcription). This can
result in false-positive results by RT-PCR (Jung et al, 1999).
However, based on the fact that our negative control (lymph nodes
of patients with chronic inflammatory bowel disease) was consis-
tently negative, we did not observe this phenomenon. A solution
for the problem of illegitimate transcription may be the use of
quantitative PCR methods by which a cut-off level for a given
primer pair could be established in order to consider a given RT-
PCR reaction to be positive.
The high rate of mRNA detection in lymph nodes of patients
without recurrence, which is also observed in studies reported in
the literature (Futamura et al, 1998), could possibly be explained
through postoperative contamination, as described. In comparison
to immunohistochemical analysis, molecular biological methods
do not allow morphological evaluation of lymph nodes and even
haematoxylin-eosin staining, as performed in our study, cannot
exclude single-cell contamination. This phenomenon can influ-
ence the results of a RT-PCR assay (Fujiwara et al, 2000).
In summary, this study confirms that the examination of
tumour-associated lymph nodes in colorectal cancer by RT-PCR
can be clinically relevant since it can predict tumour recurrence. If
this procedure is only performed on a limited number of lymph
nodes, it could prove useful as a potential strategy for the routine
clinical setting. The selection of the target gene for mRNA detec-
tion is an important factor, which has to be further evaluated in
future studies, since CK-20 and CEA showed little differences for
the prediction of tumour recurrence. Studies with larger patient
groups will be needed to confirm our results and to demonstrate
statistical significance for the prognostic significance of these
markers. In addition, immunohistochemical staining of lymph-
node sections parallel with PCR analysis is needed for morpho-
logical examination of sections, allowing the role of potential
contamination of specimens with tumour cells to be demonstrated.
Finally, the establishment of quantitative methods for the defini-
tion of biologically relevant tumour deposits in the lymph nodes of
colorectal carcinoma might be an interesting addition to this
promising technique.
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Figure 3 Kaplan–Meier curve showing disease-free survival of patients with
lymph nodes positive and negative for CK-20 mRNA (A) and CEA mRNA (B).
The patients with a negative CK-20 or CEA RT-PCR have a tendency for
longer disease-free survival than those with CK-20 or CEA positivity (n.s.)
(CK 20-negative relapse rate 3/20 (15%), CK20-positive relapse rate 9/31
(29%), CEA-negative relapse rate 3/21 (14%), CEA-positive relapse rate 9/30
(30%))
Table 3 Study comparison showing the available data on clinical significance of RT-PCR detection of CK-20 or CEA mRNA in locoregional lymph nodes of
colorectal cancer (pN0)
Study RT-PCR positive LN for Patients with Impact on
Patients (n)  Lymph nodes CK-20 CEA PCR pos. cells prognosis
(n) n % n % n %
Futamura 1998 13 202 81 40.0 95 47.0 13 100.0 n.e.
Liefers 1998 26 192 n.e. – 36 18.7 14 53.8 yes
Mori 1998 65a 406 n.e. – 245 60.3 44 67.6 yes
Own results 51 102 62 60.8 60 58.8 37 72.5 n.s.
aColorectal (n = 20), gastric (n = 31), breast (n = 10) and oesophageal (n = 4) cancer patients; n.e. = not examined; n.s. = not significantCEA and CK-20 mRNA in lymph nodes of colorectal carcinoma 1329
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